<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0610200190
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Esperoct
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TUROCTOCOG ALFA PEGOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1504.749
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novo Nordisk Bagsvaerd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novo Nordisk Bagsvaerd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Esperoct<sup>&reg;</sup> is</strong></p><p>Esperoct<sup>&reg;</sup> contains the active substance turoctocog&nbsp;alfa&nbsp;pegol and is a long‑acting recombinant coagulation factor&nbsp;VIII product. Factor&nbsp;VIII is a protein found in the blood that helps to prevent and stop bleeding.</p><p><strong>&nbsp;</strong></p><p><strong>What Esperoct<sup>&reg;</sup> is used for</strong></p><p>Esperoct<sup>&reg;</sup> is used to treat and prevent bleeding with haemophilia&nbsp;A (inborn factor&nbsp;VIII deficiency).</p><p>&nbsp;</p><p>In people with haemophilia&nbsp;A, factor&nbsp;VIII is missing or does not work properly. Esperoct<sup>&reg;</sup> replaces this faulty or missing factor&nbsp;VIII and helps blood to form clots at the site of bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Esperoct</strong><strong><sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to hamster proteins.</p><p>&nbsp;</p><p>Do not use Esperoct<sup>&reg;</sup> if either of the above applies to you. If you are not sure, talk to your doctor before using this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>Previous use of factor&nbsp;VIII medicine</strong></p><p>Tell your doctor<strong> </strong>if you have used factor&nbsp;VIII medicines before, especially if you developed inhibitors (antibodies) against the medicine, since there might be a risk that it happens again.</p><p>&nbsp;</p><p><strong>Allergic reactions</strong></p><p>There is a risk that you may experience a severe and sudden allergic reaction (e.g. anaphylactic reaction) to Esperoct<sup>&reg;</sup>.</p><p>&nbsp;</p><p>Stop the injection and contact your doctor or an emergency unit immediately if you have early signs of allergic reactions. These early signs may include rash, hives, weals, itching on large areas of skin, redness and/or swelling of lips, tongue, face or hands, difficulty in swallowing or breathing, wheezing, tightness of the chest, pale and cold skin, fast heartbeat, or dizziness, headache, nausea and vomiting.</p><p>&nbsp;</p><p><strong>Development of &lsquo;factor VIII inhibitors&rsquo; (antibodies)</strong></p><p>Inhibitors (antibodies) can develop during the treatment with all factor&nbsp;VIII medicines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These inhibitors, especially at high levels, stop the treatment working properly</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be monitored carefully for development of these inhibitors</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your bleeding is not being controlled with Esperoct<sup>&reg;</sup>, tell your doctor immediately</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not increase the total dose of Esperoct<sup>&reg;</sup> to control your bleed without talking to your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Immune system response</strong></p><p>A transient response from your immune system might occur in the beginning of your treatment, which could make your medicine work less well.</p><p>&nbsp;</p><p><strong>Catheter‑related problems</strong></p><p>If you have a catheter where medicines can be injected into your blood (central venous access device), you may develop infections or blood clots at the site of the catheter.</p><p>&nbsp;</p><p><strong>Heart disease</strong></p><p>Talk to your doctor or pharmacist if you have heart disease or you are at risk of heart disease.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and Esperoct<sup>&reg;</sup></strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Esperoct<sup>&reg;</sup> has no influence on your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Esperoct<sup>&reg;</sup> contains sodium</strong></p><p>This medicine contains 30.5&nbsp;mg sodium (main component of cooking/table salt) per reconstituted vial. This is equivalent to 1.5% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p><strong>Decreased factor VIII activity in previously treated patients</strong></p><p>A decreased factor VIII activity may occur in the beginning of your treatment. If you think your medicine works less than expected, tell your doctor<u>.</u></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Esperoct<sup>&reg;</sup> will be started by a doctor who is experienced in the care of people with haemophilia A.</p><p>&nbsp;</p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure about how to use Esperoct<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>How Esperoct<sup>&reg;</sup> is given</strong></p><p>Esperoct<sup>&reg;</sup> is given as an injection into a vein (intravenously), see &lsquo;Instructions on how to use Esperoct<sup>&reg;</sup>&rsquo; for more information.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>Your doctor will calculate your dose for you. This will depend on your body weight and whether it is used to prevent or to treat a bleeding.</p><p>&nbsp;</p><p><strong>To prevent bleeding</strong></p><p>Adults and adolescents (12&nbsp;years of age and above): The recommended dose is 50&nbsp;IU of Esperoct<sup>&reg;</sup> per kg body weight every 4&nbsp;days. Your doctor may choose another dose or how often the injections should be given, based on your need.</p><p>&nbsp;</p><p>Children (&lt; 12 years): A dose of 65 IU of Esperoct<sup>&reg;</sup> per kg body weight twice weekly. This regimen</p><p>may be individually adjusted to less or more frequent dosing based on bleeding episodes.</p><p>&nbsp;</p><p><strong>To treat bleeding</strong></p><p>The dose of Esperoct<sup>&reg;</sup> is calculated depending on your body weight and the factor&nbsp;VIII levels to be achieved. The target factor&nbsp;VIII levels will depend on the severity and location of the bleeding. If you experience that the effect of Esperoct<sup>&reg;</sup> is insufficient, talk to your doctor.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Adolescents (12 years of age and above)&nbsp; can use the same dose as adults.</p><p>Esperoct<strong><sup>&reg;</sup></strong> can be used in children. Your healthcare provider will decide the dose of Esperoct you will receive</p><p>&nbsp;</p><p><strong>If you use more Esperoct<sup>&reg;</sup> than you should</strong></p><p>If you use more Esperoct<sup>&reg;</sup> than you should, contact your doctor straight away.</p><p>&nbsp;</p><p>If you have to significantly increase your usage of Esperoct<sup>&reg;</sup> to stop a bleed, talk to your doctor immediately. For further information, see &lsquo;Development of &lsquo;factor VIII inhibitors&rsquo; (antibodies)&rsquo; in section 2.</p><p>&nbsp;</p><p><strong>If you forget to use Esperoct<sup>&reg;</sup></strong></p><p>If you forget a dose, inject the missed dose as soon as you remember. Do not inject a double dose to make up for a forgotten dose. Proceed with the next injection as scheduled and continue as advised by your doctor. If you are in doubt, contact your doctor.</p><p>&nbsp;</p><p><strong>If you stop using Esperoct<sup>&reg;</sup></strong></p><p>Do not stop using Esperoct<sup>&reg;</sup> without talking to your doctor.</p><p>If you stop using Esperoct<sup>&reg;</sup>, you may no longer be protected against bleeding or a current bleed may not stop. If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Allergic reactions (hypersensitivity)</strong></p><p>Stop the injection immediately if you develop severe and sudden allergic reactions (anaphylactic reactions). You must contact your doctor or an emergency unit immediately if you have signs of an allergic reaction such as:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in swallowing or breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness and/or swelling of the lips, tongue, face or hands</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, hives, weals or itching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pale and cold skin, fast heartbeat, or dizziness (low blood pressure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, nausea or vomiting.</p><p>&nbsp;</p><p><strong>Development of &lsquo;factor VIII inhibitors&rsquo; (antibodies)</strong></p><p>If you have previously received more than 150&nbsp;days of treatment with factor&nbsp;VIII, inhibitors (antibodies) may develop (may affect up to 1 in 100&nbsp;people). If this happens, your medicine may stop working properly and you may experience persistent bleeding. If this happens, you should contact your doctor immediately. See &lsquo;Development of &lsquo;factor VIII&nbsp;inhibitors&rsquo; (antibodies)&rsquo; in section 2.</p><p><strong>&nbsp;</strong></p><p><strong>The following side effects have been observed with Esperoct</strong><strong><sup>&reg;</sup></strong></p><p><strong><sup>&nbsp;</sup></strong></p><p><strong>Very common side effects</strong><strong> (may affect more than up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; factor VIII inhibitors (antibodies) in patients not previously treated with factor VIII.</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10&nbsp;people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions where the injection is given</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of skin (erythema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash.</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100&nbsp;people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (hypersensitivity). These may become severe and could be life‑threatening, see &lsquo;Allergic reactions (hypersensitivity)&rsquo; above for more information</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; factor&nbsp;VIII inhibitors (antibodies) in patients previously treated with factor&nbsp;VIII.</p><p><strong>&nbsp;</strong></p><p><strong>Other possible side effects (unknown frequency)</strong></p><p>Decreased factor VIII activity in the absence of factor VIII inhibitors.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated after &lsquo;Expiry&rsquo; on the carton, on the vial, and on the pre‑filled syringe labels. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Before reconstitution </strong>(before the powder is mixed with the solvent):</p><p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C). Esperoct<sup>&reg;</sup> can be kept</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at room temperature (&le;&nbsp;30&deg;C) for a single period for up to 12&nbsp;months within the shelf life of the product <strong>or</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; above room temperature (&gt;&nbsp;30&deg;C up to 40&deg;C) for a single period for up to 3&nbsp;months within the shelf life of the product.</p><p>&nbsp;</p><p>When you start to store Esperoct<sup>&reg;</sup> outside the refrigerator, record the date and the storage temperature in the space provided on the carton.</p><p>Once you have taken the product out of the refrigerator for storage you must not store it again in the refrigerator. Do not freeze. Store in the original package in order to protect from light.</p><p>&nbsp;</p><p><strong>After reconstitution</strong> (after the powder has been mixed with the solvent):</p><p>Once you have reconstituted Esperoct<sup>&reg;</sup>, it should be used immediately. If you cannot use the reconstituted solution immediately, it should be used within</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24&nbsp;hours when stored in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C) <strong>or</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;hours at &le;&nbsp;30&deg;C <strong>or</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;hour between &gt;&nbsp;30&deg;C and 40&deg;C, only if the product was stored above room temperature (&gt;&nbsp;30&deg;C up to 40&deg;C) before reconstitution for no longer than 3&nbsp;months.</p><p>&nbsp;</p><p>The powder in the vial appears as a white to off‑white powder. Do not use the powder if the colour has changed.</p><p>&nbsp;</p><p>The reconstituted solution must be clear and colourless. Do not use the reconstituted solution if you notice any particles or discolouration.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Esperoct<sup>&reg;</sup> contains</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is turoctocog&nbsp;alfa&nbsp;pegol (pegylated human coagulation factor&nbsp;VIII (rDNA)). Each vial of Esperoct<sup>&reg;</sup> contains nominally 500, 1000, 1500, 2000 or 3000&nbsp;IU turoctocog&nbsp;alfa&nbsp;pegol.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are L‑histidine, sucrose, polysorbate&nbsp;80, sodium chloride, L‑methionine, calcium chloride dihydrate, sodium hydroxide and hydrochloric acid.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The ingredients in the solvent are sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection and water for injections.</p><p>&nbsp;</p><p>After reconstitution with the supplied solvent (sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection), the prepared solution for injection contains 125, 250, 375, 500 or 750&nbsp;IU turoctocog&nbsp;alfa&nbsp;pegol per ml, respectively (based on the strength of turoctocog&nbsp;alfa&nbsp;pegol, i.e. 500, 1000, 1500, 2000 or 3000&nbsp;IU).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Esperoct® looks like and contents of the pack
Esperoct® is available in packs containing 500 IU, 1000 IU, 1500 IU, 2000 IU, or 3000 IU. Each pack of Esperoct® contains a vial with white to off white powder, a 4 ml pre filled syringe with a clear colourless solvent, a plunger rod and a vial adapter.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK‑2880 Bagsv&aelig;rd, Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Feb-2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">يحتوي إسبيروكت<sup>&trade;</sup> على المادة الفعالة &rlm;‫&rlm;‫توركتوكوج ألفا بيجول، وهو أحد منتجات عامل التخثر المؤتلف الثامن طويل المفعول. العامل الثامن هو بروتين موجود طبيعياً في الدم والذي يساعد على منع ووقف النزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيمَا يُستخدم إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">يتم استخدام إسبيروكت<sup>&trade;</sup> لعلاج ومنع النزيف الذي يحدث للمرضى المصابين بمرض الهيموفيليا أ (نقص وراثي في عامل التخثر الثامن).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعاني الأشخاص المصابين بمرض &quot;الهيموفيليا أ&quot; من عدم وجود العامل الثامن لتخثر الدم أو من عدم أدائه لوظائفه كما ينبغي. يعمل إسبيروكت<sup>&trade;</sup> على تعويض وإحلال محل هذا العامل الثامن غير الموجود أو الذي به خلل، ويساعد الدم على تكوين تخثرات في موضع النزيف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه المادة الفعالة أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه بروتينات الجرذ الأرنبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم إسبيروكت<sup>&trade;</sup> إذا كانت أيٌ من الحالات أعلاه تنطبق عليك. إذا لم تكن متأكداً، فاستشر طبيبك قبل استعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أحد أدوية العامل الثامن فيما سبق</strong></p><p dir="RTL">أخبر طبيبك<strong> </strong>إذا كنت قد استخدمت أدوية العامل الثامن من قبل، خاصةً إذا كانت قد تكوّنت لديك مثبطات (أجسام مضادة) للدواء، لأنك قد تكون عُرضة لحدوث ذلك مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحساسية</strong></p><p dir="RTL">هناك احتمالية للتعرض لتفاعل حساسية حاد ومفاجئ (تفاعل تأقي) نتيجة لاستعمال إسبيروكت<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك وقف الحقن والاتصال بالطبيب أو وحدة الطوارئ على الفور إذا كان لديك علامات مبكرة على وجود تفاعلات حساسية. قد تشمل هذه العلامات المبكرة الطفح الجلدي والشرى والانتبار والحكة في مساحات كبيرة من الجلد واحمرار و/أو تورم الشفاه أو اللسان أو الوجه أو اليدين وصعوبة في البلع أو التنفس وأزيز وضيق في الصدر وشحوب وبرودة في الجلد وسرعة ضربات القلب أو الدوار وصداع وغثيان وقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تكوُّن &quot;مثبطات العامل الثامن&quot; (أجسام مضادة)</strong></p><p dir="RTL">يمكن أن تتكوّن المثبطات (الأجسام المضادة) أثناء العلاج بجميع أدوية العامل الثامن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وهذه المثبطات، وخاصةً عندما تكون بمستويات عالية، توقف العلاج عن العمل بشكل صحيح</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستتم مراقبتك عن كثب للتأكد من عدم تكوُّن هذه المثبطات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وإذا لم يتم التحكم في النزيف لديك باستخدام إسبيروكت<sup>&trade;</sup>، أخبر طبيبك على الفور</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بزيادة الجرعة الإجمالية من إسبيروكت<sup>&trade;</sup> من أجل السيطرة على النزيف بدون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استجابة الجهاز المناعي</strong></p><p dir="RTL">قد تحدث استجابة عابرة من جهازك المناعي في بداية العلاج، مما قد يجعل دوائك يعمل بشكل أقل</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل تتعلق بالقسطرة</strong></p><p dir="RTL">إذا كان لديك قسطرة تم تركيبها لحقن الأدوية في دمك (جهاز وصول مركزي وريدي)، فقد تصاب بالتهابات أو جلطات دموية في موضع القسطرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أمراض القلب</strong></p><p dir="RTL">استشِر طبيبك أو الصيدلي إذا كنت تعاني من أمراض القلب أو كنت عرضة لخطر الإصابة بأمراض القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وإسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">أخبر الطبيب إذا كنت تتناول أدوية أخرى أو تناولت أية أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">فإذا كنتِ حاملاً أو تُرضعين رضاعة طبيعية، أو إذا كنتِ تظنين أنك قد تكونين حاملاً أو كنتِ تخططين للإنجاب، استشيري الطبيب قبل أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يؤثر دواء إسبيروكت<sup>&trade;</sup> على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء إسبيروكت</strong><strong><sup>&trade;</sup></strong><strong> على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على 30.5 ملجم من الصوديوم (المكون الرئيسي لملح الطعام) في كل قنينة بعد مزجها. هذا يعادل 1.5% من الحد الأقصى الموصى به يومياً من تناول الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انخفاض نشاط العامل الثامن في المرضى الذين سبق علاجهم</strong></p><p dir="RTL">قد يحدث انخفاض في نشاط العامل الثامن في بداية علاجك. إذا كنت تعتقد أن دوائك يعمل أقل من المتوقع ، أخبر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يبدأ العلاج بدواء إسبيروكت<sup>&trade;</sup> من خلال طبيب ذي خبرة في علاج المرضى المصابين بمرض &quot;الهيموفيليا أ&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التزم دائماً باستخدام هذا الدواء بالطريقة التي يصفها لك الطبيب بالضبط. كما يجب استشارة طبيبك إذا لم تكن متأكداً من كيفية استعمال إسبيروكت<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إعطاء دواء إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">يتم إعطاء إسبيروكت<sup>&trade;</sup> عن طريق الحقن في الوريد، راجع &quot;تعليمات عن كيفية استخدام إسبيروكت<sup>&trade;</sup>&quot; لمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة الاستخدام</strong></p><p dir="RTL">سوف يقوم الطبيب باحتساب الجرعة التي تناسبك. وهذا سيعتمد على وزنك وما إذا كان الدواء يُستخدم لمنع النزيف أو لعلاجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لمنع النزيف</strong></p><p dir="RTL">البالغون والمراهقون (12 عاماً فما فوق): الجرعة الموصى بها هي 50 وحدة دولية من إسبيروكت<sup>&trade;</sup> لكل كيلوجرام من وزن الجسم كل 4 أيام. قد يختار طبيبك جرعة أخرى أو معدل آخر لتكرار الحقن، بناءً على حاجتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال (أقل من 12 سنة): جرعة 65 وحدة دولية من الإسبروكت<sup>&trade;</sup> &nbsp;لكل كيلوغرام من وزن الجسم مرتين أسبوعياً. هذه الجرعة</p><p dir="RTL">يمكن تعديلها بشكل فردي إلى جرعات أقل أو أكثر بناءً على نوبات النزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج النزيف</strong></p><p dir="RTL">يتم احتساب جرعة إسبيروكت<sup>&trade;</sup> حسب وزن الجسم ومستويات عامل التخثر الثامن المطلوب تحقيقها. وتعتمد المستويات المستهدفة لعامل التخثر الثامن على شِدة النزيف وموضعه. إذا شعرت أن تأثير إسبيروكت<sup>&trade;</sup> غير كافٍ، استشِر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن استعماله للأطفال والمراهقين</strong></p><p dir="RTL">يمكن للمراهقين (البالغين 12 عاماً فما فوق) استخدام نفس جرعات البالغين.</p><p dir="RTL">يمكن استخدام إسبيروكت&trade;، في الأطفال. سيقرر مقدم الرعاية الصحية الخاص بك جرعة إسبيروكت&trade; التي ستتلقاها</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من إسبيروكت</strong><strong><sup>&trade;</sup></strong><strong> عن الجرعة الموصوفة</strong></p><p dir="RTL">في حالة استخدام جرعة زائدة من إسبيروكت<sup>&trade;</sup>، اتصل بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت في حاجة إلى زيادة جرعتك من إسبيروكت<sup>&trade;</sup> لإيقاف حالة من النزيف، استشِر طبيبك على الفور. لمزيد من المعلومات، انظر &quot;&rlm;‫تكوُّن &quot;مثبطات العامل الثامن&quot; (أجسام مضادة)&quot; في القسم 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">في حالة نسيان جرعة، ينبغي حقن الجرعة الفائتة في أسرع وقت بمجرد تذكرها. لا تحقن جرعة مضاعفة لتعويض الجرعة التي فاتتك. عليك أخذ الحقنة التالية في موعدها المقرر والمتابعة حسب ما أشار طبيبك. يجب استشارة طبيبك في حالة الشك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام دواء إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">لا تتوقف عن استخدام إسبيروكت<sup>&trade;</sup> دون استشارة طبيبك.</p><p dir="RTL">في حالة التوقف عن استخدام إسبيروكت<sup>&trade;</sup>، فأنت لم تعد في حماية من حدوث نزيف أو قد لا تتوقف حالة النزيف الحالية. إذا كانت لديك أية أسئلة إضافية حول استعمال هذا الدواء، فيمكنك سؤال الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية وإن كانت لا تحدث لدى جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية (فرط الحساسية)</strong></p><p dir="RTL">يجب التوقف عن الحقن فوراً في حالة حدوث تفاعل حساسية حاد ومفاجئ (تفاعلات تأقية). يجب عليك الاتصال بالطبيب أو وحدة الطوارئ على الفور إذا كان لديك علامات على وجود تفاعل حساسية مثل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع أو التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار و/أو تورم الشفاه أو اللسان أو الوجه أو اليدين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي أو الشرى أو الانتبار أو الحكة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شحوب وبرودة في الجلد أو سرعة ضربات القلب أو الدوار (انخفاض ضغط الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع أو غثيان أو قيء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تكوُّن &quot;مثبطات العامل الثامن&quot; (أجسام مضادة)</strong></p><p dir="RTL">إذا تلقيت سابقاً أكثر من 150 يوماً من العلاج بأدوية العامل الثامن، فقد تتكوّن مثبطات (أجسام مضادة) (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص). وإذا حدث هذا، قد لا يعمل الدواء بشكل صحيح وقد تعاني من نزيف مستمر. وإذا حدث هذا، يجب الاتصال بطبيبك على الفور. انظر &quot;تكوُّن مثبطات العامل الثامن (أجسام مضادة)&quot; في القسم 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظت الآثار الجانبية التالية مع العلاج بدواء إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong><u>آثار جانبية شائعة جدا </u></strong><u>(قد تؤثر على أكثر من 1 من كل 10 أشخاص)</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>مثبطات العامل الثامن (الأجسام المضادة) في المرضى الذين لم يعالجوا سابقا بالعامل الثامن.</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong>(قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫تفاعلات جلدية في موضع الحقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد (التهاب احمراري للجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong>(قد تصيب ما يصل إلى شخص واحد من كل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (فرط الحساسية). &rlm;‫قد تصبح شديدة ويمكن أن تكون مهددة للحياة، انظر &quot;تفاعلات الحساسية (فرط الحساسية)&quot; أعلاه لمزيد من المعلومات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات العامل الثامن (الأجسام المضادة) في المرضى الذين عولجوا سابقاً بأدوية العامل الثامن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية محتملة أخرى (شيوع غير معروف)</strong></p><p dir="RTL">انخفاض نشاط العامل الثامن في غياب مثبطات العامل الثامن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">في حالة إصابتك بأي آثار جانبية، استشر الطبيب أو الصيدلي أو الممرض. يشمل هذا أية آثار جانبية محتملة غير واردة في هذه النشرة. فبالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون بعد كلمة &quot;Expiry&quot; على العبوة الكرتونية وعلى القنينة وعلى ملصقات الحُقن المعبأة مسبقاً. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل المزج </strong>(قبل مزج المسحوق بالمذيب):</p><p dir="RTL">يُخزن في الثلاجة (في درجة حرارة 2 إلى 8 درجات مئوية) يمكن تخزين إسبيروكت<sup>&trade;</sup></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في درجة حرارة الغرفة (في درجة حرارة 30 درجة مئوية أو أقل) لفترة واحدة تصل إلى 12 شهراً خلال مدة صلاحية المنتج <strong>أو</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلى من درجة حرارة الغرفة (في درجة حرارة أعلى من 30 درجة مئوية وحتى 40 درجة مئوية) لفترة واحدة تصل إلى 3 أشهر خلال مدة صلاحية المنتج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما تبدأ في تخزين إسبيروكت<sup>&trade;</sup> خارج الثلاجة، قم بتسجيل التاريخ ودرجة حرارة التخزين في المساحة المخصصة لذلك على العبوة الكرتونية.</p><p dir="RTL">بمجرد إخراج المنتج من الثلاجة للتخزين، يجب عدم تخزينه مرة أخرى في الثلاجة. يُراعى عدم التجميد. يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعد المزج</strong> (بعد مزج المسحوق بالمذيب):</p><p dir="RTL">بمجرد مزج محلول إسبيروكت<sup>&trade;</sup>، يجب استخدامه في الحال. إذا لم تتمكن من استخدام المحلول الممزوج على الفور، فيجب استخدامه خلال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24 ساعة في حالة تخزينه في الثلاجة (في درجة حرارة 2 إلى 8 درجات مئوية) <strong>أو</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 ساعات في حالة تخزينه في درجة حرارة 30 درجة مئوية أو أقل <strong>أو</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساعة واحدة في حالة تخزينه في درجة حرارة تتراوح بين ما يزيد عن 30 درجة مئوية و40 درجة مئوية، فقط إذا تم تخزين المنتج فوق درجة حرارة الغرفة (أعلى من 30 درجة مئوية وحتى 40 درجة مئوية) قبل المزج لمدة لا تزيد عن 3 أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يظهر المسحوق الموجود في القنينة على شكل مسحوق لونه أبيض إلى أبيض مائل للاصفرار. لا تستخدم المسحوق إذا تغير لونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يكون المحلول الممزوج صافياً وعديم اللون. لا تستخدم المحلول الممزوج إذا لاحظت وجود جزيئيات داخله أو إذا تغير لونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات دواء إسبيروكت</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ‫&rlm;‫&rlm;‫توركتوكوج ألفا بيجول (عامل التخثر الثامن البشري المُبلمر(rDNA)). تحتوي كل قنينة من إسبيروكت<sup>&trade;</sup> اعتبارياً على 500 أو 1000 أو 1500 أو2000 أو 3000 وحدة دولية من &rlm;‫&rlm;‫توركتوكوج ألفا بيجول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتشكل المكونات الأخرى من إل-هيستيدين وسكروز وبوليسوربات 80 وكلوريد الصوديوم وإل-ميثيونين وكلوريد كالسيوم ثنائي الهيدرات وهيدروكسيد الصوديوم وحمض الهيدروكلوريك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; والمكونات الموجودة في المذيب هي محلول للحقن من كلوريد الصوديوم 9 ملجم/مل 0.9)&rlm;%( وماء للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد المزج بالمذيب الملحق (محلول للحقن من كلوريد الصوديوم 9 ملجم/مل 0.9)&rlm;%()، سوف يحتوي محلول الحقن الذي تم تحضيره على 125 أو 250 أو 375 أو 500 أو 750 وحدة دولية من &rlm;‫&rlm;‫توركتوكوج ألفا بيجول لكل مل على التوالي (وفقاً لتركيز توركتوكوج ألفا بيجول، أي 500 أو 1000 أو 1500 أو 2000 أو 3000 وحدة دولية).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل إسبيروكت</strong><strong><sup>&trade;</sup></strong><strong> ومحتويات العبوة</strong></p><p dir="RTL">يتوفر إسبيروكت<sup>&trade;</sup> في عبوات تحتوي على 500 وحدة دولية أو 1000 وحدة دولية أو 1500 وحدة دولية أو 2000 وحدة دولية أو 3000 وحدة دولية. تحتوي كل عبوة من إسبيروكت<sup>&trade;</sup> على قنينة بها مسحوق أبيض أو أبيض مائل للاصفرار، وحقنة معبأة مسبقاً 4 مل تحتوي على مذيب صافٍ عديم اللون، وذراع كبّاس ومهايئ للقنينة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK‑2880 Bagsv&aelig;rd, Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير - 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esperoct 500 IU powder and solvent for solution for injection 
Esperoct 1000 IU powder and solvent for solution for injection 
Esperoct 1500 IU powder and solvent for solution for injection 
Esperoct 2000 IU powder and solvent for solution for injection 
Esperoct 3000 IU powder and solvent for solution for injection.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esperoct 500 IU powder and solvent for solution for injection
Each powder vial contains nominally 500 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 125 IU turoctocog alfa pegol.

Esperoct 1000 IU powder and solvent for solution for injection
Each powder vial contains nominally 1000 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 250 IU turoctocog alfa pegol.

Esperoct 1500 IU powder and solvent for solution for injection
Each powder vial contains nominally 1500 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 375 IU turoctocog alfa pegol.

Esperoct 2000 IU powder and solvent for solution for injection
Each powder vial contains nominally 2000 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 500 IU turoctocog alfa pegol.

Esperoct 3000 IU powder and solvent for solution for injection
Each powder vial contains nominally 3000 IU turoctocog alfa pegol*.
After reconstitution, 1 mL of solution contains approximately 750 IU turoctocog alfa pegol.

The potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific activity of turoctocog alfa pegol is approximately 9500 IU/mg protein.

The active substance turoctocog alfa pegol is a covalent conjugate of the protein turoctocog alfa* with a 40 kDa polyethylene-glycol (PEG).

*Human factor VIII, produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) cell line, and no additives of human or animal origin are used in the cell culture, purification, conjugation or formulation of Esperoct.

Excipient with known effect
Each reconstituted vial contains 30.5 mg of sodium (see section 4.4). For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection
the powder is white to off-white
the solvent is clear and colourless 
pH: 6.9
Osmolality: 590 mOsmol/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia.</p><p><u>Treatment monitoring</u></p><p>During the course of treatment, appropriate determination of factor VIII activity levels is advised to guide adjustments of the dosing regimen of Esperoct, if needed. Individual patients may vary in their response to factor VIII, demonstrating different half-lives and incremental recoveries. Dose based on bodyweight may require adjustment in underweight or overweight patients. In the case of major surgical interventions in particular, monitoring of the factor VIII substitution therapy by measurement of plasma factor VIII activity is necessary.</p><p>&nbsp;</p><p>The factor VIII activity of Esperoct can be measured using the conventional factor VIII assays, the chromogenic assay and the one-stage assay.</p><p>When using an in vitro thromboplastin time (aPTT)-based one stage clotting assay for determining factor VIII activity in patients&rsquo; blood samples, plasma factor VIII activity results can be significantly affected by both the type of aPTT reagent and the reference standard used in the assay.</p><p>When using a one-stage clotting assay some silica based reagents should be avoided as they cause underestimation. Also there can be significant discrepancies between assay results obtained by aPTT- based one stage clotting assay and the chromogenic assay according to Ph. Eur. This is of importance particularly when changing the laboratory and/or reagents used in the assay.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The dose, dosing interval and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding, on the targeted factor VIII activity</p><p>level and the patient&rsquo;s clinical condition. The number of units of factor VIII administered is expressed in International Units (IU), which is related to the current WHO concentrate standard for factor VIII products. The activity of factor VIII in plasma is expressed either as percentage (relative to normal human plasma level) or in International Units per dL (relative to the current International Standard for factor VIII in plasma).</p><p>One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml of human plasma.</p><p>&nbsp;</p><p><u>On demand treatment and treatment of bleeding episodes</u></p><p>The calculation of the required dose of factor VIII is based on the empirical finding that</p><p>1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dL.</p><p>The required dose is determined using the following formula:</p><p>Required units (IU) = body weight (kg) x desired factor VIII rise (%) (IU/dL) x 0.5 (IU/kg per IU/dL).</p><p>The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.</p><p>&nbsp;</p><p>Guidance for the dosing of Esperoct for the on-demand treatment and treatment of bleeding episodes is provided in table 1. Plasma factor VIII activity levels should be maintained at or above the described plasma levels (in IU per dL or % of normal). For treatment of bleeds a maximum single dose of Esperoct at 75 IU/kg and a maximum total dose of 200 IU/kg/24 hours may be administered.</p><p>&nbsp;</p><p><strong>Table 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guidance for treatment of bleeding episodes with Esperoct</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:647px"><tbody><tr><td style="vertical-align:top"><p><strong>Degree of haemorrhage</strong></p></td><td style="vertical-align:top"><p><strong>Factor VIII level required (IU/dL or % of normal)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Frequency of doses (hours)</strong></p></td><td style="vertical-align:top"><p><strong>Duration of therapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Mild</strong></p><p>Early haemarthrosis, mild muscle bleeding or mild oral bleeding</p></td><td style="vertical-align:top"><p>20-40</p></td><td style="vertical-align:top"><p>12-24</p></td><td style="vertical-align:top"><p>Until the bleeding is resolved</p></td></tr><tr><td style="vertical-align:top"><p><strong>Moderate</strong></p><p>More extensive haemarthrosis, muscle bleeding, haematoma</p></td><td style="vertical-align:top"><p>30-60</p></td><td style="vertical-align:top"><p>12-24</p></td><td style="vertical-align:top"><p>Until the bleeding is resolved</p></td></tr><tr><td style="vertical-align:top"><p><strong>Severe or</strong></p><p><strong>life-threatening haemorrhages</strong></p></td><td style="vertical-align:top"><p>60-100</p></td><td style="vertical-align:top"><p>8-24</p></td><td style="vertical-align:top"><p>Until the threat is resolved</p></td></tr></tbody></table><p><sup>a</sup> The required dose is determined using the following formula:</p><p>Required units (IU) = body weight (kg) x desired factor VIII rise (%) (IU/dL) x 0.5 (IU/kg per IU/dL).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Children (&lt; 12 years): 65 IU/kg body weight for minor/moderate/major bleeds.</p><p><u>&nbsp;</u></p><p><u>Perioperative management</u></p><p>The dose level and dosing intervals for surgery depend on the procedure and local practice. A maximum single dose of Esperoct at 75 IU/kg and a maximum total dose of 200 IU/kg/24 hours may be administered.</p><p>The frequency of doses and duration of therapy should always be individually adjusted based on individual clinical response.</p><p>&nbsp;</p><p>Table 2 includes general recommendation for dosing of Esperoct for perioperative management. Consideration should be given to maintain a factor VIII activity at or above the target range.</p><p><strong>Table 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guidance for dosing of Esperoct for perioperative management</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Type of surgical procedure</strong></p></td><td style="vertical-align:top"><p><strong>Factor VIII level required (%) (IU/dL)</strong><sup>a</sup></p></td><td style="vertical-align:top"><p><strong>Frequency of doses (hours)</strong></p></td><td style="vertical-align:top"><p><strong>Duration of therapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Minor surgery </strong>Including tooth extraction</p></td><td style="vertical-align:top"><p>30-60</p></td><td style="vertical-align:top"><p>Within one hour before surgery</p><p>Repeat after 24 hours if necessary</p></td><td style="vertical-align:top"><p>Single dose or repeat injection every 24 hours for at least 1 day until healing is achieved</p></td></tr><tr><td style="vertical-align:top"><p><strong>Major surgery</strong></p></td><td style="vertical-align:top"><p>80-100</p><p>(pre- and post-operative)</p></td><td style="vertical-align:top"><p>Within one hour before surgery to achieve factor VIII activity within the target range</p><p><strong>&nbsp;</strong></p><p>Repeat every 8 to 24 hours to maintain factor VIII activity within the target range</p></td><td style="vertical-align:top"><p>Repeat injection every 8 to 24 hours as necessary until adequate wound healing is achieved</p><p><strong>&nbsp;</strong></p><p>Consider to continue therapy for another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dL)</p></td></tr></tbody></table><p><sup>a</sup> The required dose is determined using the following formula:</p><p>Required units (IU) = body weight (kg) x desired factor VIII rise (%) (IU/dL) x 0.5 (IU/kg per IU/dL).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Children (&lt; 12 years): 65 IU/kg body weight. Frequency of administration is determined by the treating physician.</p><p><em>&nbsp;</em></p><p><em>Prophylaxis</em></p><p>The recommended dose is 50 IU of Esperoct per kg body weight every 4 days.</p><p>Adjustments of doses and administration intervals may be considered based on achieved factor VIII levels and individual bleeding tendency.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The dose in adolescents (12 years and above) is the same as for adults.</p><p>Children (&lt; 12 years): A dose of 65 IU of Esperoct per kg body weight twice weekly. This regimen may be individually adjusted to less or more frequent dosing based on bleeding episodes.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>Esperoct is for intravenous use.</p><p>Esperoct should be administered by intravenous injection (over approximately 2 minutes) after reconstitution of the powder with 4 mL supplied solvent (sodium chloride 9 mg/mL (0.9%) solution for injection).</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Known allergic reaction to hamster protein.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve traceability of biological medicinal products, the name and the batch number of the administraered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Allergic-type hypersensitivity reactions are possible with Esperoct. The product contains traces of hamster proteins, which in some patients may cause allergic reactions. If symptoms of hypersensitivity occur, patients should be advised to immediately discontinue the use of the medicinal product and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.</p><p>In case of shock, standard medical treatment for shock should be implemented.</p><p><u>Inhibitors</u></p><p>The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII pro-coagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay. The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 50 exposure days but continues throughout life although the risk is uncommon.</p><p>&nbsp;</p><p>The clinical relevance of inhibitor development will depend on the titre of the inhibitor, with low titre posing less of a risk of insufficient clinical response than high titre inhibitors.</p><p>In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests. If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.</p><p><u>&nbsp;</u></p><p><u>Decreased factor VIII activity in previously treated patients</u></p><p>From post marketing reports, a decreased factor VIII activity in the absence of detectable factor VIII inhibitors has been reported in previously treated patients. The decreased factor VIII activity was observed at time of switching to Esperoct and may, in some cases, have been associated with anti-PEG antibodies. Appropriate determination of factor VIII activity upon switching should be considered.</p><p>See section 4.8 for additional information.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Cardiovascular events</u></p><p>In patients with existing cardiovascular risk factors, substitution therapy with factor VIII may increase the cardiovascular risk.</p><p>&nbsp;</p><p><u>Catheter-related complications</u></p><p>If a central venous access device (CVAD) is required, the risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The listed warnings and precautions apply both to adolescents and children.</p><p>&nbsp;</p><p><u>Treatment response in previously untreated patients</u></p><p>In some previously untreated patients a decreased FVIII recovery has been observed in the absence of detectable Factor VIII inhibitors. When observed, the decreased FVIII recovery occurred after a few exposures to Esperoct&reg; and was generally transient. Monitoring of previously untreated patients including</p><p>monitoring of post dose FVIII activity is recommended.</p><p>&nbsp;</p><p><u>Excipient-related considerations</u></p><p>The medicinal product contains 30.5 mg sodium per reconstituted vial, equivalent to 1.5% of the WHO recommended maximum daily intake of 2.0 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions of human coagulation factor VIII (rDNA) with other medicinal products have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal reproduction studies have not been conducted with factor VIII. Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast-feeding is not available. Therefore, factor VIII should be used during pregnancy and lactation only if clearly indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esperoct has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely and may in some cases progress to severe anaphylaxis (including shock).</p><p>&nbsp;</p><p>Very rarely development of antibodies to hamster protein with related hypersensitivity reactions has been observed.</p><p>&nbsp;</p><p>Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with Esperoct. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre is contacted.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of adverse reactions as observed in 270 unique subjects across five prospective, multi-centre clinical studies in previously treated patients (PTPs) with severe haemophilia A (&lt;1% endogenous factor VIII activity) and no history of inhibitors are listed in table 3. The categories of adverse reactions presented in table 3 is according to the MedDRA system organ classification (SOC and Preferred Term Level).</p><p>Frequencies have been evaluated according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency of adverse reactions in clinical trials for PTPs*</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Factor VIII inhibition</p></td><td style="vertical-align:top"><p>Uncommon (PTPs)**</p><p>Very common (PUPs)*</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash Erythema Pruritus</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration sites conditions</p></td><td style="vertical-align:top"><p>Injection site reactions***</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Coagulation factor VIII level decreased</p></td><td style="vertical-align:top"><p>Unknown****</p></td></tr></tbody></table><p>* PTPs: Previously-treated patients. PUPs: Previously untreated patients.</p><p>** Frequency is based on studies with all factor VIII products which included patients with severe haemophilia A.</p><p>*** Preferred terms included in injection site reactions: Injection site reaction, Vessel puncture site haematoma, Infusion site reaction, Injection site erythema, Injection site rash, Vessel puncture site pain, and Injection site swelling.</p><p>**** Based on post marketing reports.</p><p><u>Description of selected adverse reactions</u></p><p><em>Factor VIII inhibitors</em></p><p>One confirmed case of factor VIII inhibitor occurred in an 18 year-old previously treated patient on prophylactic treatment with Esperoct. The patient had a factor VIII gene intron 22 inversion and was at a high risk of developing factor VIII inhibitors.</p><p>There is no indication of an increased risk of factor VIII inhibitor development with treatment of Esperoct as compared to other factor VIII products.</p><p>&nbsp;</p><p><em>Anti-drug antibodies</em></p><p>There was one case of persistent anti-drug antibodies concomitant with the confirmed case of factor VIII inhibitors (see <em>Factor VIII inhibitors)</em>. Three patients had transiently positive test results for anti-drug antibodies after administration of Esperoct but no correlation with adverse events could be established.</p><p>&nbsp;</p><p><em>Anti-PEG antibodies</em></p><p>During the clinical trial programme, thirty-two patients had pre-existing anti-PEG antibodies before administration of Esperoct. Twenty of the 32 patients were negative for anti-PEG antibodies post administration of Esperoct. Eleven patients developed transient low titre anti-PEG antibodies. No correlation with adverse events could be established.</p><p>From post-marketing reporting, occurrence of anti-PEG-antibodies has also been observed at time of switching to Esperoct. In some patients anti-PEG antibodies may have been associated with lower than expected level of FVIII activity.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>No difference in the safety profile of Esperoct&reg; was observed between previously treated pediatric subjects and adult subjects.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_2" o:spid="_x0000_s1027"
 style='position:absolute;margin-left:108.95pt;margin-top:53.95pt;width:54pt;
 height:.5pt;z-index:251659264;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="blue" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="72" height="1" src="file:///C:/Users/abbd/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance and Drug Safety Center (NPC).</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:66.25pt;
  margin-top:27.5pt;width:360.7pt;height:94.55pt;z-index:-251655168;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight="1pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:5.35pt;margin-right:0in;margin-bottom:
     0in;margin-left:35.9pt;text-indent:-18.05pt;line-height:normal;mso-pagination:
     none;mso-list:l0 level1 lfo2;tab-stops:35.9pt 35.95pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-GB style='font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB>The
     National Pharmacovigilance and Drug Safety Centre<span style='letter-spacing:
     -.3pt'> </span>(NPC)<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:5.3pt;margin-right:0in;margin-bottom:
     6.0pt;margin-left:17.9pt;tab-stops:35.9pt'><span lang=EN-GB>–<span
     style='mso-tab-count:1'>     </span>Fax: +966-11-205-7662<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:35.9pt;text-indent:-18.05pt;line-height:12.6pt;mso-line-height-rule:
     exactly;mso-pagination:none;mso-list:l1 level1 lfo1;tab-stops:35.9pt 35.95pt;
     text-autospace:none'><![if !supportLists]><span lang=EN-GB
     style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
     style='mso-list:Ignore'>–<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB>SFDA
     Call<span style='letter-spacing:-.05pt'> </span>Center:19999<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:35.9pt;text-indent:-18.05pt;line-height:12.6pt;mso-line-height-rule:
     exactly;mso-pagination:none;mso-list:l1 level1 lfo1;tab-stops:35.9pt 35.95pt;
     text-autospace:none'><![if !supportLists]><span lang=EN-GB
     style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
     style='mso-list:Ignore'>–<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB>E-mail:<span
     style='color:blue'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:blue'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:35.9pt;text-indent:-18.05pt;line-height:normal;mso-pagination:
     none;mso-list:l1 level1 lfo1;tab-stops:35.9pt 35.95pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-GB style='font-family:"Times New Roman",serif;mso-fareast-font-family:
     "Times New Roman"'><span style='mso-list:Ignore'>–<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB>Website:<a
     href="https://ade.sfda.gov.sa/"><span style='color:blue'>https://ade.sfda.gov.sa/</span></a><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><p>&nbsp;</p><p>To report any side effect(s):</p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center:19999</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No symptoms of overdose with recombinant coagulation factor VIII have been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihemorrhagics, blood coagulation factor VIII, ATC code: B02BD02.</p><p><u>Mechanism of action</u></p><p>Turoctocog alfa pegol is a purified recombinant human factor VIII (rFVIII) product with a 40 kDa polyethylene-glycol (PEG) conjugated to the protein. The PEG is attached to the O-linked glycan in the truncated B-domain of rFVIII (turoctocog alfa). The mechanism of action of turoctocog alfa pegol is based on the replacement of the deficient or absent factor VIII in patients with haemophilia A. When turoctocog alfa pegol is activated by thrombin at the site of injury, the B-domain containing the PEG moiety and the a3-region are cleaved off, thus generating activated recombinant factor VIII (rFVIIIa) which is similar in structure to native factor VIIIa.</p><p>The factor VIII/von Willebrand factor complex consists of two molecules (factor VIII and von Willebrand factor) with different physiological functions. When injected into a haemophiliac patient, factor VIII binds to von Willebrand factor in the patient&rsquo;s circulation. Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as results of accidental or surgical trauma. By factor VIII replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.</p><p>&nbsp;</p><p><u>Clinical efficacy during prophylaxis and treatment of bleeding episodes</u></p><p>The clinical efficacy of Esperoct for prophylaxis and treatment of bleeds was investigated in five prospective, multi-centre clinical studies in 270 previously treated patients (PTPs) with severe haemophilia A.</p><p>&nbsp;</p><p><u>Prophylaxis in adults/adolescents</u></p><p>The efficacy of Esperoct for prophylaxis and treatment of bleeds was evaluated in an open-label, non-controlled trial in adolescents and adult patients with severe haemophilia A ages 12 years and above. The prophylactic effect of Esperoct was demonstrated with a dosing at 50 IU per kg body weight every 4 days or every 3&ndash;4 days (twice weekly) in 175 patients. The median annualised bleeding rate (ABR) in adults and adolescents receiving Esperoct was 1.18 (Interquartile range IQR:</p><p>0.00;4.25), whereas the spontaneous ABR was 0.00 (IQR: 0.00;1.82), traumatic ABR was 0.00 (IQR: 0.00;1.74) and joint ABR was 0.85 (IQR: 0.00;2.84). When including imputations, (replacing missing data for withdrawn patients with a substituted value) the estimated mean ABR for all bleeds was</p><p>3.70 (95% CI: 2.94;4.66). Of the 175 adults/adolescents on prophylaxis, 70 (40%) did not have any bleeds. The mean annual consumption for prophylaxis was 4641 IU/kg.</p><p>&nbsp;</p><p>Of note, annualized bleeding rate (ABR) is not comparable between different factor concentrates and between different clinical studies.</p><p>&nbsp;</p><p>Adults/adolescents who had a low bleeding rate of 0-2 bleeding episodes during the last 6 months and had obtained at least 50 doses of Esperoct had the option of being randomised to prophylaxis treatment every 7 days (75 IU/kg every 7 days) or every 4 days (50 IU/kg every 4 days). A total of 55 of the 120 eligible patients chose to be randomised (17 to the every 4 days dosing and 38 to the 75 IU every</p><p>7 days). The ABR for randomised patients was 1.77 (0.59; 5.32) for treatment every 4 days and 3.57 (2.13; 6.00) for once weekly prophylaxis. Nine of these patients reverted back to prophylaxis every</p><p>4 days during the randomised study phase. Overall, including all extensions parts, 31 of 61 patients on every 7 days prophylaxis switched back to every 4 days treatment.</p><p>&nbsp;</p><p>Overall, 68 children below 12 years received prophylactic treatment with Esperoct at an average dose of approximately 65 IU/kg twice weekly. The prophylactic effect of Esperoct was demonstrated with a median ABR rate of 2.0 (IQR: 0.0; 2.8) and 2.0 (IQR: 0.0; 4.2) for treated bleeds and all bleeds respectively (see Table 8). The mean ABR (SD) for treated bleeds and all bleeds were 3.1 (7.1) and 4.4 (8.7), respectively. Of the 68 children, 22 (32%) did not experience any bleeding episodes and 29 (43%) did not experience any bleeding episodes that required treatment during the Main Phase of the trial. Of the 13 subjects with 17 documented target joints at baseline, 10 subjects (77%) and 14 target joints (82%) did not have any bleeds during the Main Phase of the trial.</p><p>&nbsp;</p><p>Prophylaxis in previously untreated patients (PUPs) (below 6 years)</p><p>The efficacy and safety of Esperoct were evaluated in a multi-national, non-randomised, open label phase 3 trial. Pre-prophylaxis (optional on-demand treatment for bleeding episodes and/or dosing of 60 IU/kg at intervals longer than a week until the subject reached 20 exposure days (EDs) or turned 24 months of age) and prophylaxis treatment of bleeds were evaluated in 81 PUPs below 6 years with severe haemophilia A. Of the total 81 patients, 55 patients started on pre-prophylaxis and 42 of those patients then switched to prophylaxis. In total 69 patients received prophylaxis treatment with a dosing at 60 IU per kg body weight (50-75 IU/kg) twice weekly.</p><p>The prophylactic effect of Esperoct in PUPs below 6 years with severe haemophilia A was demonstrated with a median and estimated mean annualized bleeding rate of 1.35 and 2.27 (95% CI: 1.71;3.01).</p><p>Of note, annualized bleeding rate (ABR) is not comparable between different factor concentrates and between different clinical studies.</p><p>The haemostatic response success rate for the 69 PUPs below 6 years on prophylaxis was 92.5% in treatment of bleeding episodes.</p><p>The mean annual consumption for the 69 PUPs on prophylaxis was 5,395 IU/kg.</p><p>In the trial, a total of 56 adverse reactions in 43 of 81 patients and a total of 80 serious adverse events in 48 patients were reported after exposure to Esperoct.</p><p>In 31 out of 59 PUPs without inhibitors, transiently decreased factor VIII incremental recovery (IR) has been observed after exposure to Esperoct. There were 17 PUPs with consecutive measurements of decreased IR, all of these subjects had anti-PEG IgG antibodies. An association between anti-PEG antibodies and low IR cannot be excluded.</p><p>&nbsp;</p><p><u>Clinical efficacy of Esperoct in treatment of bleeding episodes and during on-demand treatment</u></p><p>The efficacy of Esperoct in the treatment of bleeding episodes was demonstrated in all age groups. The vast majority of bleeds treated with Esperoct were of mild/moderate severity.</p><p>The overall success rate for the treatment of bleeds was 87.7% and 94.4% of all bleeds treated with 1-2 injections.</p><p>&nbsp;</p><p>In 12 patients above 18 years of age, 1,126 bleedings were treated among patients receiving</p><p>on-demand treatment with an average treatment dose of 38.1 IU/kg with a mean annual consumption of 1457 IU/kg. Of the total 1,126 bleeds, 86.9% were effectively treated with 1 injection and 96.8% were effectively treated with 1-2 injections of Esperoct.</p><p>&nbsp;</p><p><u>Clinical efficacy of Esperoct during major surgery</u></p><p>Esperoct was effective in maintaining haemostasis during major surgery with a success rate of 95.6% in all major surgeries performed (43 out of 45 had the effect rated as &lsquo;excellent&lsquo; or &lsquo;good&lsquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In total, 129 single-dose pharmacokinetic (PK) profiles of Esperoct were evaluated in 86 patients (including 24 paediatric patients of 0 to below 12 years).</p><p>All pharmacokinetic studies with Esperoct were conducted in previously treated patients with severe haemophilia A (factor VIII &lt;1%). Patients received a single dose of 50 IU/kg, and blood samples were collected prior to dosing and at multiple time points up to 96 hours after dosing.</p><p>The half-life of Esperoct was 1.6 fold longer compared to unmodified factor VIII products in adults. <u>Pharmacokinetic parameters</u></p><p>A total of 108 single dose pharmacokinetic profiles at 50 IU/kg Esperoct were evaluated in</p><p>69 patients. The single dose pharmacokinetic parameters are comparable between young children (0 to below 6 years) and older children (6 to below 12 years), and between adolescents (12 to17 years) and adults (18 years and above).</p><p>As expected incremental recovery appeared to be lower while body weight adjusted clearance appeared to be higher in children compared to adults and adolescents. In general, there was a trend of increasing incremental recovery and decreasing clearance (mL/h/kg) with age. This corresponds to a higher volume of distribution per kilo body weight in children compared to adults (table 4).</p><p>The single dose pharmacokinetic parameters determined after 28 weeks of prophylactic treatment with Esperoct were consistent with the initial pharmacokinetic parameters.</p><p>&nbsp;</p><p>Single-dose pharmacokinetic parameters of Esperoct are listed in table 4.</p><p><strong>Table 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Single-dose pharmacokinetic parameters of Esperoct 50 IU/kg in children, adolescents and adults by age using the chromogenic assay (geometric mean [CV%])</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:666px"><tbody><tr><td style="vertical-align:top"><p>PK Parameter N=No. of patients</p></td><td style="vertical-align:top"><p>0 to below 6 years N=13</p></td><td style="vertical-align:top"><p>6 to below 12 years N=11</p></td><td style="vertical-align:top"><p>12 to below18 years</p><p>N=3</p></td><td style="vertical-align:top"><p>18 years and above N=42</p></td></tr><tr><td style="vertical-align:top"><p>Number of profiles</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>79</p></td></tr><tr><td style="vertical-align:top"><p>IR (IU/dL) per (IU/kg)<sup>a</sup></p></td><td style="vertical-align:top"><p>1.80 (29)</p></td><td style="vertical-align:top"><p>1.99 (25)</p></td><td style="vertical-align:top"><p>2.79 (12)</p></td><td style="vertical-align:top"><p>2.63 (22)</p></td></tr><tr><td style="vertical-align:top"><p>Maximum</p><p>factor VIII activity (IU/dL)<sup>a</sup></p></td><td style="vertical-align:top"><p>101.2 (28)</p></td><td style="vertical-align:top"><p>119.6 (25)</p></td><td style="vertical-align:top"><p>133.2 (9)</p></td><td style="vertical-align:top"><p>134.4 (23)</p></td></tr><tr><td style="vertical-align:top"><p>t1/2 (hours)</p></td><td style="vertical-align:top"><p>13.6 (20)</p></td><td style="vertical-align:top"><p>14.2 (26)</p></td><td style="vertical-align:top"><p>15.8 (43)</p></td><td style="vertical-align:top"><p>19.9 (34)</p></td></tr><tr><td style="vertical-align:top"><p>AUCinf (IU*hour/dL)</p></td><td style="vertical-align:top"><p>2147 (47)</p></td><td style="vertical-align:top"><p>2503 (42)</p></td><td style="vertical-align:top"><p>3100 (44)</p></td><td style="vertical-align:top"><p>3686 (35)</p></td></tr><tr><td style="vertical-align:top"><p>CL (mL/hour/kg)</p></td><td style="vertical-align:top"><p>2.6 (45)</p></td><td style="vertical-align:top"><p>2.4 (40)</p></td><td style="vertical-align:top"><p>1.5 (43)</p></td><td style="vertical-align:top"><p>1.4 (32)</p></td></tr><tr><td style="vertical-align:top"><p>Vss (mL/kg)</p></td><td style="vertical-align:top"><p>44.2 (34)</p></td><td style="vertical-align:top"><p>41.2 (25)</p></td><td style="vertical-align:top"><p>33.4 (10)</p></td><td style="vertical-align:top"><p>37.7 (27)</p></td></tr><tr><td style="vertical-align:top"><p>MRT (hours)</p></td><td style="vertical-align:top"><p>17.0 (22)</p></td><td style="vertical-align:top"><p>17.3 (31)</p></td><td style="vertical-align:top"><p>21.7 (45)</p></td><td style="vertical-align:top"><p>25.2 (29)<sup>b</sup></p></td></tr></tbody></table><p>Abbreviations: AUC = area under the factor VIII activity time profile; t1/2 = terminal half-life; MRT = mean residence time; CL = clearance; Vss = volume of distribution at steady&ndash;state; IR = Incremental recovery.</p><p><sup>a</sup> Incremental recovery and factor VIII were assessed 30 min post-dosing for patients 12 years and above and 60 min post-dosing (first sample) for children below12 years.</p><p><sup>b</sup> Calculation based on 67 profiles.</p><p>&nbsp;</p><p>The mean trough plasma factor VIII activity levels at steady&ndash;state during prophylactic treatment with Esperoct dosed with 50 IU/kg every 4 days is 3.0 IU/dL (95% CI: 2.6;3.4) in patients 12 years and above</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special concern for humans based on conventional studies of safety pharmacology and repeated dose toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Sodium chloride</p><p>&nbsp;L-Histidine</p><p>Sucrose</p><p>Polysorbate 80</p><p>L-Methionine</p><p>Calcium chloride dihydrate</p><p>Sodium hydroxide (for pH adjustment)</p><p>Hydrochloric acid (for pH adjustment)</p><p>&nbsp;</p><p><u>Solvent</u></p><p>Sodium chloride</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products or reconstituted with injection solutions other than the provided sodium chloride solvent.</p><p>The reconstituted product should not be administered in the same tubing or container with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial (before reconstitution):
36 months when stored in a refrigerator (2°C – 8°C).
During the shelf life the product may be kept:
•	at room temperature (≤30°C) for a single period no longer than 12 months
or
•	above room temperature (>30°C up to 40°C) for a single period no longer than 3 months
Once the product has been stored outside of the refrigerator, the product must not be returned for storage in the refrigerator.
Record the beginning of storage outside refrigerator and the storage temperature in the space provided on the carton.

After reconstitution
Chemical and physical in-use stability have been demonstrated for:
•	24 hours when stored in a refrigerator (2°C - 8°C) or
•	4 hours at ≤30°C or
•	1 hour between ˃30°C and 40°C, only if the product was stored above room temperature (˃30°C up to 40°C) before reconstitution for no longer than 3 months.
From a microbiological point of view, the product should be used immediately after reconstitution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the users and would normally not be recommended for longer than as stated above, unless reconstitution has taken place in controlled and validated aseptic conditions.

The reconstituted solution should be stored in the vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage at room temperature (&le;30&deg;C) or up to 40&deg;C and storage conditions after reconstitution of</p><p>the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each pack of Esperoct contains:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 glass vial (type I) with powder closed with a chlorobutyl rubber stopper, an aluminium seal with a plastic snap-off cap</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 sterile vial adapter for reconstitution</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 pre-filled syringe of 4 mL solvent with backstop (polypropylene), a rubber plunger (bromobutyl) and a rubber tip cap (bromobutyl)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 plunger rod (polypropylene).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esperoct is to be administered intravenously after reconstitution of the powder with the solvent supplied in the syringe. After reconstitution the solution appears as a clear and colourless liquid free of visible particles. The reconstituted medicinal product should be inspected visually for particulate matter and discolouration prior to administration. The solution should be clear and colourless. Do not use solutions that are cloudy or have deposits.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see the package leaflet.</p><p>&nbsp;</p><p>The rate of administration should be determined by the patient&rsquo;s comfort level over approximately 2 minutes.</p><p>&nbsp;</p><p>An infusion set (butterfly needle with tubing), sterile alcohol swabs, gauze pads and plasters will also be needed. These devices are not included in the Esperoct package.</p><p>Always use an aseptic technique.</p><p><u>Disposal</u></p><p>After the injection, safely dispose of the syringe with the infusion set and the vial with the vial adapter. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd 
Denmark


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>